Iovance Biotherapeutics (IOVA) Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. IMNN
9. NAVN
10. NVDA

Go back to Iovance Biotherapeutics (IOVA) Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

May 27, 2020 4:02 PM EDT

Cohort 4 Early Data Shows 32.4% ORR by Investigator Assessment at 5.3 Months of Median Study Follow up

Cohort 2 Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up and 36.4% ORR

SAN CARLOS, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced initial data from pivotal Cohort 4 and updated long-term data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.

We are very pleased to announce... More